Skip to main content

Komen to Fund Cancer PGx Research through New Grants

NEW YORK (GenomeWeb News) – Susan G. Komen for the Cure, a non-profit organization dedicated to funding breast cancer research and education, has awarded $60 million in grants to US and international researchers, including nearly $19 million to fund research into pharmacogenomics.

The funding for the pharmacogenomic research is provided through the organization's Promise Grants.

Komen, along with the Triple Negative Breast Cancer Foundation, has awarded $6.4 million to the University of Alabama at Birmingham to study adding a new drug, along with chemotherapy in treating triple negative breast cancer. That research project includes looking for ways to predict which therapies will be most effective for triple negative breast cancer patients.

Indiana University will receive a $5.8 million Promise Grant to identify biomarkers to predict which breast cancer patients will benefit from the drug bevacizumab (Avastin), and which patients will suffer significant side effects from use of the drug.

Researchers at Thomas Jefferson University in Philadelphia will use a $6.7 million Promise Grant to find biomarkers to predict treatment response and match patients with the best treatment option.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.